ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

トリプロリジン

Triprolidine

HCID 5282443
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
486-12-4
標準SMILES
Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
InChIKey
CBEQULMOCCWAQT-WOJGMQOQSA-N
分子式
C19H22N2
平均分子量
278.4 g/mol
単同位体質量
278.17829871

概要

Triprolidine is an N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders. It has a role as a H1-receptor antagonist. It is a member of pyridines, a N-alkylpyrrolidine and an olefinic compound. It is a conjugate base of a triprolidine(1+).

名称と識別子

優先名称
Triprolidine
IUPAC
2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine
現地名
トリプロリジン
英語名
Triprolidine
分子式
C19H22N2
分子量
278.39

名称と別名

triprolidine486-12-4TriprolidinActidilTripolidinaTriprolidinumTriprolidina2-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridineDTXSID3023718trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-eneNCI-C61450trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene
名称をさらに表示
2-[(E)-3-(1-ピロリジニル)-1-(p-トリル)-1-プロペニル]ピリジントリプロリジン2-[(E)-1-(4-メチルフェニル)-3-(1-ピロリジニル)-1-プロペニル]ピリジン2-[(1E)-3-(1-ピロリジニル)-1-p-トリル-1-プロペニル]ピリジントリピロリジントランス-1-(4-メチルフェニル)-1-(2-ピリジル)-3-ピロリジノ-1-プロペン2-[(1E)-1-(4-メチルフェニル)-3-ピロリジノ-1-プロペニル]ピリジン1-[γ-(2-ピリジル)-4-メチル-cis-シンナミル]ピロリジン2-[(E)-3-(1-ピロリジニル)-1-p-トリル-1-プロペニル]ピリジン2-[(1E)-1-(4-メチルフェニル)-3-(ピロリジン-1-イル)プロパ-1-エン-1-イル]ピリジン(e)-pyridinTripyrolidineTriprolidine USP/EP/BPTriprolidine (Standard)(E)-1-(2-pyridyl)-3-pyrrolidin-1-yl-1-p-tolylpropene
2L8T9S52QM2-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridineDTXCID203718CHEBI:84116Pyridine, 2-(3-(1-pyrrolidinyl)-1-p-tolylpropenyl)-, (E)-trans-2-(3-(1-Pyrrolidinyl)-1-p-tolylpropenyl)pyridine(E)-2-[3-(1-Pyrrolidinyl)-1-p-toluenepropenyl]pyridine(E)-2-(3-(1-pyrrolidinyl)-1-p-toluenepropenyl)pyridine

物性

構造計算による物性補完中

XLogP
3.9
極性表面積
16.1 Ų
水素結合供与体数
0
水素結合受容体数
2
回転可能結合数
4
重原子数
21
形式電荷
0
複雑度
335

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 件

4

3.87

Color/FormCrystals from light petroleum
Solubility5.37e-02 g/L
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Antihistamines

Pharmaceuticals

Melting Point · 2 件

59-61 °C

60 °C

Physical DescriptionSolid
Dissociation Constants · 2 件

9.69

9.25

Collision Cross Section167.67 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Other Safety InformationIMAP assessments - Pyridine, 2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-, (E)-: Environment tier I assessment
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

Concurrent use /of ototoxic medications/ with antihistamines may mask the symptoms of ototoxicity such as tinnitus, dizziness, or vertigo. /Antihistamines/

Concurrent use of monoamine oxidase (MAO) inhibitors with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines; concurrent use is not recommended. /Antihistamines/

Concurrent use /with alcohol or other CNS depression-producing medications/ may potentiate the CNS depressant effects of either these medications or antihistamines; also, concurrent use of maprotiline or tricyclic antidepressants may potentiate the anticholinergic effects of either antihistamines or these medications. /Antihistamines/

Anticholinergic effects may be potentiated when /anticholinergics or other medications with anticholinergic activity/ are used concurrently with antihistamines; patients should be advised to report occurrence of gastrointestinal problems promptly since paralytic ileus may occur with concurrent therapy. /Antihistamines/

化学と産業

薬理情報

ATC Code · 2 件

R - Respiratory system

QR - Respiratory system

Pharmacodynamics · 1 件

In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Triprolidine, is a histamine H1 antagonist that competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies. Triprolidine has anticholinergic and sedative effects.

Mechanism of Action · 6 件

Triprolidine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

Antihistamines used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. They thereby prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus. Also, the anticholinergic actions of most antihistamines provide a drying effect on the nasal mucosa. /Antihistamines/

Antihistamines used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. They thereby prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus. Also, the anticholinergic actions of most antihistamines provide a drying effect on the nasal mucosa. /Antihistamines/

H1 antagonists inhibit most responses of smooth muscle to histamine. Antagonism of the constrictor action of histamine on respiratory smooth muscle is easily shown in vivo and in vitro. /Histamine Antagonists: H1 Antagonists/

関連反応

7 件
反応記録を作成
HRID 1803087 の反応式
HRID 1803087生成物として
HRID 1803088 の反応式
HRID 1803088反応物として
HRID 1803089 の反応式
HRID 1803089生成物として
HRID 1803090 の反応式
HRID 1803090反応物として
HRID 1803091 の反応式
HRID 1803091生成物として
HRID 1803092 の反応式
HRID 1803092反応物として
HRID 2250421 の反応式
HRID 2250421生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
486-12-4
PubChem CID
5282443
DTXSID
DTXSID3023718
ChEMBL
CHEMBL855
ChEBI
CHEBI:84116
UNII
2L8T9S52QM
EC Number
207-627-0
Nikkaji
J6.005D
59 · 59-61°
沸点
435.4 · 435.4±34.0 °C(Predicted)
比重(密度)
1.061 · 1.061±0.06 g/cm3(Predicted)
酸解離定数(Pka)
4.01 · pKa 4.01(H2O t = 23.0) (Uncertain);9.69(H2O t = 23.0) (Uncertain)
CAS データベース
486 · 486-12-4(CAS DataBase Reference)
NISTの化学物質情報
Triprolidine(486-12-4)

For more Interactions (Complete) data for TRIPROLIDINE (10 total), please visit the HSDB record page.

HepatotoxicityLike most first generation antihistamines, triprolidine has not been linked to liver test abnormalities or to clinically apparent liver injury. The reason for its safety may relate its use in low dose for short periods only.
Ongoing Test Status · 1 件

The following link will take the user to the National Toxicology Program (NTP) Test Agent Search Results page, which tabulates all of the "Standard Toxicology & Carcinogenesis Studies", "Developmental Studies", and "Genetic Toxicity Studies" performed with this chemical. Clicking on the "Testing Status" link will take the user to the status (i.e., in review, in progress, in preparation, on test, completed, etc.) and results of all the studies that the NTP has done on this chemical. [http://ntp-apps.niehs.nih.gov/ntp_tox/index.cfm?fuseaction=ntpsearch.searchresults&searchterm=486-12-4]

Human Toxicity Excerpts · 4 件

In acute poisoning with H1 antagonists, their central excitatory effects constitute the greatest danger. The syndrome includes hallucinations, excitement, ataxia, incoordination, athetosis, and convulsions. Fixed, dilated pupils with a flushed face, together with sinus tachycardia, urinary retention, dry mouth, and fever, lend the syndrome a remarkable similarity to that of atropine poisoning. Terminally, there is deepening coma with cardiorespiratory collapse and death, usuallY within 2 to 18 hours. Treatment is along general symptomatic and supportive lines. /Histamine Antagonists: H1 Antagonists/

... SIDE EFFECTS INCL DRYNESS OF ... RESP PASSAGES, SOMETIMES INDUCING COUGH; URINARY FREQUENCY & DYSURIA; PALPITATION; HYPOTENSION; HEADACHE; TIGHTNESS OF CHEST; TINGLING, HEAVINESS, & WEAKNESS OF HANDS. ... ALLERGIC DERMATITIS IS NOT UNCOMMON. /ANTIHISTAMINES/

IN SMALL CHILD ... SYNDROME OF POISONING INCL ... ATAXIA, INCOORDINATION, ATHETOSIS ... FIXED, DILATED PUPILS WITH FLUSHED FACE ... ARE COMMON. /ANTIHISTAMINES/

ALTHOUGH H1-BLOCKING DRUGS HAVE RELATIVELY HIGH MARGIN OF SAFETY, ACUTE POISONING WITH THEM IS COMMON. ... IN CHILDREN, 20 TO 30 TABLETS OR CAPSULES OF MOST COMMERCIALLY AVAILABLE ANTIHISTAMINES REPRESENTS LETHAL OR NEAR-LETHAL DOSE. /ANTIHISTAMINES/

Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

triprolidine

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity Excerpts · 2 件

Externally tested on the eyes of rabbits and found to have a toxicity rating of 5, according to the degree of injury observed after 24 hr. The test is based on a scale of 1-10, with 1 being the least amount of injury.

H1 blockers are among the many drugs that induce hepatic microsomal enzymes, and they may facilitate their own metabolism. /Histamine Antagonists: H1 Antagonists/

Populations at Special Risk · 2 件

Use is not recommended in newborn or premature infants because this age group has an increased susceptibility to anticholinergic side effects, such as central nervous system excitation, and an increased tendency toward convulsions. A paradoxical reaction characterized by hyperexcitability may occur in children taking antihistamines. /Antihistamines/

Dizziness, sedation, confusion, and hypotension may be more likely to occur in geriatric patients taking antihistamines. Geriatric patients are especially susceptible to the anticholinergic side effects, such as dryness of mouth and urinary retention (especially in males), of the antihistamines. If these side effects occur and continue or are severe, medication should probably be discontinued. /Antihistamines/

Antidote and Emergency Treatment · 1 件

THERE IS NO SPECIFIC THERAPY FOR ANTIHISTAMINE POISONING, AND TREATMENT IS ALONG GENERAL SYMPTOMATIC AND SUPPORTIVE LINES. ... SHOULD BREATHING FAIL, MECH SUPPORT OF VENTILATION OFFER SAFER AND ... EFFECTIVE MEANS OF MAINTAINING RESP THAN USE OF ANALEPTICS WHICH ARE PRONE TO INITIATE OR INTENSIFY CONVULSIVE PHASE. /ANTIHISTAMINES/

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

有毒物質データの
486-12-4(Hazardous Substances Data)

/SRP:/ The action of histamine results in increased permeability and formation of edema and wheal. H1 antagonists block that action.

For more Mechanism of Action (Complete) data for TRIPROLIDINE (7 total), please visit the HSDB record page.

Biological Half-Life · 2 件

4 to 6 hours.

Elimination: 3 to 3.3 hours

Metabolism/MetabolitesMAIN SITE OF METABOLIC TRANSFORMATION IS LIVER. /ANTIHISTAMINES/
MeSH Pharmacological Classification · 2 件

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood.

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)

Absorption, Distribution and Excretion · 3 件

Rapidly absorbed in the intestinal tract.

The H1 antagonists are well absorbed from the GI tract. Following oral administration, peak plasma concn are achieved in 2 to 3 hr and effects usually last 4 to 6 hr; however, some of the drugs are much longer acting ... . /Histamine Antagonists: H1 Antagonists/

... H1 antagonists are eliminated more rapidly by children than by adults and more slowly in those with severe liver disease. /Histamine Antagonists: H1 Antagonists/

Cellular LocationsExtracellular
Metabolite PathwaysTriprolidine H1-Antihistamine Action

用途と製造

Uses · 2 件

MEDICATION

Use (kg; approx.) in Germany (2009): >25

U.S. Production(1985) 9.57X10+7 g /Antihistamines including triprolidine hydrochloride/
Methods of ManufacturingA commercial reaction is that of 2-pyrridyllithium with the appropriate Mannich ketone to give alcohol which, on dehydration, yields the antihistamine triprolidine
Formulations/PreparationsActidil, Actidilon, Alleract; Pro-actidil, Pro-Entra, Venen 295.C.51. /Triprolidine hydrochloride monohydrate/
Use ClassificationPharmaceuticals
General Manufacturing InformationAdamson, US patents 2,712,020, 2,712,023 (both 1955 to Burroughs Wellcome); Adamson et al, J Chem Soc 1958, 312.

応用分野

使用Antihistaminic.

上流・下流製品情報

上流原料

ピロリジンリチウムイオン4'-メチルアセトフェノンパラホルムアルデヒド2-ブロモピリジン
補足説明 · 1 件

定義ChEBI: An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms o uticaria, rhinitis, and various pruritic skin disorders.